Organ dysfunction following hematopoietic stem cell transplantation (HSCT) may be a manifestation of a systemic inflammatory response. We speculate that part of the platelet transfusion requirement in HSCT patients results from this systemic inflammatory response, and increased transfusion requirement would be associated with, or precede, organ dysfunction. We studied 199 adults undergoing autologous (n = 173) or allogeneic (n = 26) HSCT. Patients with CNS (P = 0.008) or pulmonary (P = 0.002) dysfunction, or with VOD (P = 0.05) received a higher mean number of platelet transfusions per week than patients who did not have these dysfunctions. Furthermore, a higher number of platelet transfusions during any 1 week period was significantly associated with development of pulmonary (P = 0.0002) or renal (P Ͻ 0.0001) dysfunction in the following week. This predictive value was strongest early in the HSCT course, but remained significant over all 4 weeks. In multivariate analysis the number of platelet transfusions during the previous week was independently predictive for development of pulmonary dysfunction in week 2 (P = 0.01) and week 3 (P = 0.055). We believe that occurrence of increased platelet transfusion requirement prior to onset of dysfunction is consistent with the concept that an antecedent inflammatory response results in both platelet consumption and various organ dysfunctions. Increased platelet transfusion requirement may act as an early marker of subsequent organ dysfunction. Additionally, there may be a direct role of platelets in the development and progression of organ dysfunction in HSCT patients. Keywords: thrombocytopenia; multiple organ dysfunction; syndrome; VOD; transfusion Thrombocytopenia following high-dose therapy and hematopoietic stem cell transplantation (HSCT) is an almost universal phenomenon. The duration of thrombocytopenia is probably related to both quantity and quality of stem cells reinfused,
but may also be related to other events during the period of pancytopenia, including therapy-related complications. One particular complication, veno-occlusive disease (VOD) of the liver, has been associated with both thrombocytopenia and refractoriness to platelet transfusion. 2, 3 Hepatic VOD is associated with deficiencies in circulating anticoagulants protein C (PC) and antithrombin III, 4 and with an increased risk of progression to multiple organ failure and death. 5 We have previously shown that other organ dysfunctions, such as those involving the lungs and CNS, are also associated with deficiencies in these anticoagulants, and are risk factors for progression to multiorgan failure and death. 6 In that study, development of pulmonary dysfunction, defined as need for supplemental oxygen, was associated with a 3.7-fold higher risk of subsequent hepatic VOD (P = 0.02) and a 4.9-fold higher risk of dying (P = 0.006). Similarly, development of CNS dysfunction, defined as any mental status change, was associated with a five-fold higher risk of subsequent VOD (P = 0.002) and a 4.9-fold higher risk of dying (P = 0.03).
It seems likely that these dysfunctions, including VOD, are parts of a systemic abnormality occurring after highdose therapy. This systemic abnormality bears a strong resemblance to the multiple organ dysfunction syndrome (MODS) 7 which occurs in patients with infection, multiple trauma and burns. MODS occurring in non-transplant patients is clearly associated with deficiencies in natural anticoagulants, progressive organ dysfunction and thrombocytopenia. The mechanism of thrombocytopenia is unclear, but may be related to the effects of certain cytokines (such as platelet activating factor, PAF, or tumor necrosis factor) which are associated with MODS. Platelets activated in this manner may bind to endothelial cells in the microvasculature, and this activation and binding may potentiate organ dysfunction. [8] [9] [10] In this study, we examined a large group of patients undergoing high-dose therapy with stem cell transplantation, in an attempt to describe the relationship between platelet transfusions and development of organ dysfunction.
Materials and methods

Patients
The study group comprised 199 consecutive consenting adult patients undergoing autologous or allogeneic hemato-poietic stem cell transplantation at the University of Nebraska Medical Center over a 15-month period (from 1 March 1991 to 1 June 1992). Characteristics of these patients are summarized in Table 1. A variety of preparative regimens were used based on the diagnosis, but 183 of 199 (92%) were prepared with one of seven regimens: (1) cyclophosphamide, BCNU, etoposide (CBV; 54 patients); (2) cyclophosphamide and TBI (CY/TBI; 38 patients); (3) cyclophosphamide, thioTEPA and hydroxyurea (CTH; 26 patients); (4) BCNU, etoposide, cyclophosphamide, hydroxyurea (BECH; 25 patients); (5) BCNU, etoposide, ara-C, cyclophosphamide (BEAC; 15 patients); (6) etoposide, cyclophosphamide and TBI (VP/CY/TBI; 15 patients); and (7) ifosphamide, carboplatinum and etoposide (ICE; 10 patients). The preparative regimen included total body irradiation in 58 cases (29%). These regimens have been described previously. 6 
Transplant practices
Standard post-HSCT practices at UNMC have been previously reported. 11 Because the adverse events occurring after HSCT were postulated to be related to the toxicity of the preparative regimens, the first day of the preparative regimen is considered 'day 1' in this report. Patients received total parenteral nutrition from day 1 of the transplant course until they recovered from mucositis and were able to take nutrition orally. All patients received 10 mg of vitamin K 1 weekly as a supplement to their parenteral nutrition solution beginning on day 1.
There were no universal criteria for transfusion of blood products. In general, single donor, apheresis platelet transfusions were administered for a platelet count of less than 20 000/mm 3 , but the decision to transfuse platelets was made by the attending physician. For the purpose of this analysis, a platelet transfusion was defined as a single event, independent of the actual number of donor units administered.
Adverse events
Patients were monitored for adverse clinical events daily during the first 28 days of their transplant course, until hospital dismissal, or until death. (1) Pulmonary dysfunction -defined as the use of supplemental oxygen. The need for supplemental oxygen was generally defined by the presence of hypoxia (as shown by oxygen saturation of less than 90% using finger oximetry). (2) Central nervous system (CNS) dysfunction -defined by the attending physician's assessment of altered mental status. (3) Renal dysfunction -defined as serum creatinine greater than 1.5 mg/dl. (4) Hepatic veno-occlusive disease -defined as either of two clinical and laboratory syndromes: (i) bilirubin Ͼ1.8 mg/dl and abdominal pain and weight gain of more than 5% over admission weight (Seattle criteria).
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(ii) bilirubin Ͼ2.0 mg/dl and two of (1) hepatomegaly, (2) ascites, (3) weight gain of more than 5% over admission weight (Hopkins criteria).
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In the text these are referred to as VOD 1 and VOD 2, respectively.
Statistical methods
Mean and maximum number of platelet transfusions over the 4-week period were computed for each patient and the Wilcoxon rank sum test was used to compare the median of these summary measures between the patients with and without organ dysfunction. Repeated measures analysis of variance was used to analyze the differences in number of platelet transfusions over the 4-week period. Logistic regression was utilized to model the probability of dysfunction as a function of the total number of transfusions received in the previous week and also for multivariate analysis. General estimating equations were used to obtain standard error estimates which acknowledge the dependence of multiple observations (ie weekly measurements) on each individual. A P value less than 0.05 was considered statistically significant.
Results
Occurrence of dysfunction
Of the 199 patients, organ dysfunction occurred in 93 (48.5%). First organ dysfunction occurred at a mean of 17.6 days after beginning the preparative regimen. In 49 of the 93, the organ dysfunction resolved within 7 days without recurrence. In the remaining 44 patients, organ dysfunction persisted for more than 7 days and/or progressed to multiple organ dysfunction. Pulmonary dysfunction occurred in 63 patients, CNS dysfunction in 59 patients, hepatic dysfunction in 15 patients, and renal dysfunction in 39 patients. Fourteen patients died prior to day 28 of the transplant course, including 10 who died of progressive multiorgan failure.
Association with platelet transfusion requirements
The mean weekly number of platelets infused for patients with and without organ dysfunction are shown in Figure With 1. Patients who experienced CNS dysfunction (P = 0.008), pulmonary dysfunction (P = 0.002), VOD 1 (P = 0.049), or VOD 2 (P = 0.05) received a higher mean number of platelet transfusions than patients who did not experience these dysfunctions. Patients who died prior to day 28 also appeared to have a higher mean number of platelet transfusions than patients who survived to day 28, but this did not quite achieve statistical significance (P = 0.056).
The difference in platelet transfusions between patients with and without organ dysfunction were also observed over the 4-week period by repeated measures analysis of variance. There were significantly more platelet transfusions given to patients with CNS dysfunction (P = 0.047), pulmonary dysfunction (P = 0.013), VOD 1 (P = 0.052), VOD 2 (P = 0.015) and renal dysfunction (P = 0.018).
The effect of number of platelet transfusions on development of organ dysfunction was also analyzed in a multivariate model. Covariates in the model included type of transplant (allogeneic vs autologous bone marrow vs autologous blood stem cell), preparative regimen and presence of infection (defined as positive blood culture). In this multivariate analysis, the number of platelet transfusions was independently predictive of development of pulmonary dysfunction (P = 0.003), CNS dysfunction (P = 0.022), liver dysfunction (P = 0.03) and renal dysfunction (P = 0.04).
The maximum number of transfusions over any 1-week period (zenith number of transfusions) was also associated with development of organ dysfunction (Figure 2 ). Patients with a higher zenith number of transfusions were more likely to develop CNS dysfunction (P = 0.004), pulmonary dysfunction (P = 0.0016), or VOD 2 (P = 0.042), and were marginally more likely to develop VOD 1 (P = 0.055), than patients with lower zenith number of transfusions. In addition, these patients were more likely to die during the 4 week period (P = 0.038).
Timing of occurrence of dysfunction and platelet transfusion
Number of platelet transfusions was also analyzed with respect to the temporal relationship to onset of organ dysfunc- tion: specifically, was the total number of platelet transfusions during any 1 week period associated with organ dysfunction in subsequent weeks? Higher numbers of platelet transfusions during any week were significantly associated with development of pulmonary dysfunction (P = 0.0002) or renal dysfunction (P Ͻ 0.0001) during the subsequent week. The strength of this association varied over the 4-week course and was most dramatic during the early weeks after therapy, but persisted throughout the 4-week period (pulmonary dysfunction, P = 0.0008; renal dysfunction P = 0.014). Furthermore, there did not appear to be a threshold effect of platelet transfusions. The risk of development of pulmonary or renal dysfunction in any 1 week period increased in a linear fashion as the number of platelet transfusions increased over the prior week (Figures 3 and 4) . We also performed the same multivariate analysis described above to determine the effect of number of platelet transfusions in the previous week on the subsequent development of organ dysfunction. In this multivariate analysis, the number of platelet transfusions during the previous week was independently predictive for development of pulmonary dysfunction in week 2 (P = 0.01) and week 3 (P = 0.055). In this analysis, the number of platelet transfusions in weeks 1 or 2 was not an independent predictor of subsequent renal dysfunction.
Discussion
It has been clearly shown that the occurrence of single organ dysfunction after hematopoietic stem cell transplantation is a risk factor for subsequent development of multiorgan dysfunction, and for death. 5, 14 At many levels, the multiorgan dysfunction that occurs after transplant resembles the MODS seen in non-transplant patients. The mechanism by which high-dose therapy or stem cell transplantation causes (or predisposes to) multiorgan dysfunction is not entirely clear. High-dose therapy has been associated with vascular endothelial damage, 15, 16 which may lead, directly or indirectly to organ dysfunction. In addition, high-dose chemotherapy or radiotherapy is associated with release of cytokines, such as TNF-␣, which may lead to or augment organ damage, 17 again, possibly through effects at the level of the vascular endothelial cell. 18 Finally, the association of MODS with ATIII and PC deficiency suggests that the hemostatic system is involved, possibly at a pathogenic level. [19] [20] [21] Thrombocytopenia is a universal finding after high-dose chemotherapy. Certainly, marrow hypoplasia and decreased thrombopoiesis plays a significant role, but basal platelet requirement may actually increase in patients who are thrombocytopenic. 22 This suggests a fixed daily requirement for platelets which may be higher in patients thrombocytopenic due to high-dose chemotherapy. Furthermore, recovery of transfused platelets in transplant patients is lower than in other groups of patients with marrow damage, 23, 24 and is even worse in transplant patients with fever, or on antibiotics. 23, 25 It has been postulated that this increased requirement is due to widespread vascular endothelial cell damage with resultant 'consumption' of platelets on the endothelial cell surface. 24 Alternatively, increased platelet consumption may be related to effects of circulating cytokines and vasoactive mediators, such as TNF-␣. Rabinowitz and co-workers 26 showed HSCT patients with higher levels of circulating TNF-␣ had a higher platelet transfusion requirement.
Rio and colleagues 2 showed that increased platelet consumption (manifest as refractoriness to platelet transfusion) was associated with one particular organ dysfunction, hepatic VOD, and that platelet refractoriness precedes the clinical manifestations of occlusive disease. McDonald and coworkers 5 confirmed this observation. They found that platelet transfusion requirements were significantly higher among patients with VOD, and the increased requirement was apparent before the onset of clinical hepatic disease. Our data suggest that the number of platelet transfusions is also associated with a variety of other organ dysfunctions, including CNS, lung and kidney as well as liver. We propose that thrombocytopenia in this setting occurs as a result of vascular endothelial damage, either as a direct consequence of the preparative regimen, or the inflammatory response produced by it. Therefore, the thrombocytopenia and increased platelet transfusion requirement can be associated with not only VOD, but virtually all organ dysfunctions occurring after HSCT.
We also sought to define whether the increase in platelet transfusions reflected a true increased platelet requirement, or reaction of the treating physician to a 'sicker patient'. We were able to show a temporal relationship between increased platelet transfusions and subsequent development of at least two organ dysfunctions (renal and pulmonary). In particular, platelet transfusion requirement during weeks 1 or 2 was independently predictive for development of pulmonary dysfunction in the subsequent week, when analyzed in a multivariate model including type of transplant, preparative regimen and presence of infection.
One interpretation of this observation is that antecedent tissue damage leads to a systemic inflammatory response, with subsequent widespread platelet consumption and organ dysfunction. Certainly, various cytokines implicated in the pathogenesis of MODS, such as platelet activating factor, are known to cause thrombocytopenia. 27, 28 Platelet refractoriness, in this situation, may be an early marker of subsequent organ dysfunction, and intervention at the onset of increased platelet consumption may be appropriate. This intervention may include treatment with agents which block the effects of these cytokines, such as PAF receptor antagonists. 29 In addition, treatment could potentially include agents which modulate the coagulopathy which accompanies non-transplant-associated MODS, such as antithrombin concentrate. 30, 31 There is already evidence suggesting a role of this agent in transplant-related organ dysfunction. 32, 33 Alternatively, or in addition, there may be a direct role of platelets in the development and progression of multiorgan dysfunction. It has been shown that consumption of platelets on the endothelial cell surface has adverse clinical consequences. Intravascular platelet aggregation releases factors that can mediate vascular endothelial cell injury. 34 Vascular endothelial cells acted upon by tumor necrosis factor and/or other cytokines express platelet binding ligands; when bound to these molecules, platelets mediate changes resulting in endothelial cell death, which can lead to hemorrhagic necrosis of the skin and, possibly, other organ injury. [8] [9] [10] Furthermore, induction of thrombocytopenia can prevent some of these experimental lesions. 10 Therefore, it is possible that prophylactic platelet transfusions, especially in escalating doses, directed at 'sick' patients, may in fact predispose to subsequent multiorgan failure. If this were the case, it might be worth considering that 'sick' thrombocytopenic patients, especially those with organ dysfunction, might be better served by restriction of platelet transfusions, perhaps for treatment of bleeding only. Further work to explore this possibility needs to be conducted.
